Freeline Therapeutics Holdings plc (NASDAQ:FRLN) Expected to Post FY2022 Earnings of ($1.54) Per Share

Freeline Therapeutics Holdings plc (NASDAQ:FRLNGet Rating) – Equities research analysts at Wedbush reduced their FY2022 earnings per share estimates for shares of Freeline Therapeutics in a report issued on Wednesday, May 11th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($1.54) per share for the year, down from their previous estimate of ($1.47). Wedbush also issued estimates for Freeline Therapeutics’ Q4 2022 earnings at ($0.24) EPS, Q1 2023 earnings at ($0.25) EPS, Q2 2023 earnings at ($0.20) EPS, Q3 2023 earnings at ($0.22) EPS, Q4 2023 earnings at ($0.24) EPS, FY2023 earnings at ($0.90) EPS, FY2024 earnings at ($0.83) EPS, FY2025 earnings at ($0.90) EPS and FY2026 earnings at ($0.76) EPS.

Freeline Therapeutics (NASDAQ:FRLNGet Rating) last released its quarterly earnings results on Tuesday, May 10th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03).

A number of other equities research analysts have also commented on the company. Zacks Investment Research lowered Freeline Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, April 4th. Stifel Nicolaus reiterated a “buy” rating on shares of Freeline Therapeutics in a research report on Friday, February 11th. Finally, Morgan Stanley lowered Freeline Therapeutics from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, February 1st. Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, Freeline Therapeutics has a consensus rating of “Buy” and a consensus price target of $10.05.

NASDAQ FRLN opened at $0.72 on Friday. Freeline Therapeutics has a one year low of $0.65 and a one year high of $15.40. The stock’s 50 day simple moving average is $0.99 and its 200 day simple moving average is $1.60.

Several large investors have recently bought and sold shares of the company. Morgan Stanley boosted its position in shares of Freeline Therapeutics by 22.9% in the 3rd quarter. Morgan Stanley now owns 41,341 shares of the company’s stock worth $141,000 after purchasing an additional 7,704 shares during the last quarter. AXA S.A. boosted its position in shares of Freeline Therapeutics by 1.9% in the 3rd quarter. AXA S.A. now owns 566,207 shares of the company’s stock worth $1,931,000 after purchasing an additional 10,452 shares during the last quarter. Citadel Advisors LLC bought a new position in shares of Freeline Therapeutics in the 2nd quarter worth $108,000. Prospera Financial Services Inc bought a new position in shares of Freeline Therapeutics in the 3rd quarter worth $51,000. Finally, Renaissance Technologies LLC boosted its position in shares of Freeline Therapeutics by 8.0% in the 4th quarter. Renaissance Technologies LLC now owns 210,100 shares of the company’s stock worth $416,000 after purchasing an additional 15,600 shares during the last quarter. Institutional investors and hedge funds own 47.05% of the company’s stock.

Freeline Therapeutics Company Profile (Get Rating)

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B.

Featured Stories

Earnings History and Estimates for Freeline Therapeutics (NASDAQ:FRLN)

Receive News & Ratings for Freeline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Freeline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.